RA15539667

RA15539667 is an irreversible covalent small molecule inhibitor of Bruton Tyrosine Kinase (BTK). Developed by Sanofi, it is being investigated for its potential to treat sickle cell disease (SCD) by modulating innate inflammatory pathways and reducing vaso-occlusion. In preclinical studies using transgenic Townes SCD mice, RA15539667 demonstrated significant efficacy in preventing microvascular stasis and lowering markers of inflammation, including total white blood cell counts and NF-κB activation in the liver. It also reduces the mobilization of adhesion molecules such as P-selectin and von Willebrand factor. By irreversibly binding to BTK, RA15539667 inhibits the signaling cascades that lead to the activation of the NLRP3 inflammasome and the subsequent release of pro-inflammatory cytokines, which are key drivers of the pathophysiology in SCD.